

J R Fraser Cummings

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7017518/publications.pdf>

Version: 2024-02-01

77
papers

6,189
citations

185998

28
h-index

128067

60
g-index

78
all docs

78
docs citations

78
times ranked

7959
citing authors

#	ARTICLE	IF	CITATIONS
1	Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. <i>Nature Genetics</i> , 2007, 39, 1329-1337.	9.4	1,298
2	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2007, 39, 830-832.	9.4	1,063
3	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	3.7	431
4	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. <i>Nature Genetics</i> , 2008, 40, 710-712.	9.4	403
5	The pattern and outcome of acute severe colitis. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 431-437.	0.6	276
6	Th17 Cells Expressing KIR3DL2+ and Responsive to HLA-B27 Homodimers Are Increased in Ankylosing Spondylitis. <i>Journal of Immunology</i> , 2011, 186, 2672-2680.	0.4	260
7	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	0.6	249
8	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	6.1	233
9	IL23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2007, 132, 1657-1664.	0.6	170
10	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	9.4	165
11	QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. <i>BMJ: British Medical Journal</i> , 1998, 316, 745-746.	2.4	122
12	Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jiw216.	0.6	118
13	Confirmation of the role of ATG16L1 as a Crohn's disease susceptibility gene. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 941-946.	0.9	98
14	Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 273-282.	3.7	91
15	Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 149-158.	0.6	85
16	Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1063-1068.	0.9	81
17	Oral methotrexate in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 385-389.	1.9	75
18	Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1641-1652.	0.9	62

#	ARTICLE	IF	CITATIONS
19	Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. <i>Frontline Gastroenterology</i> , 2020, 11, 178-187.	0.9	59
20	Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. <i>Genes and Immunity</i> , 2006, 7, 576-582.	2.2	58
21	The genetics of NOD-like receptors in Crohn's disease. <i>Tissue Antigens</i> , 2010, 76, 48-56.	1.0	56
22	Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1313-1323.	1.9	55
23	Medical management of Crohn's disease. <i>BMJ: British Medical Journal</i> , 2008, 336, 1062-1066.	2.4	52
24	MicroRNA-31 and MicroRNA-155 Are Overexpressed in Ulcerative Colitis and Regulate IL-13 Signaling by Targeting Interleukin 13 Receptor α 1. <i>Genes</i> , 2018, 9, 85.	1.0	49
25	Abnormal Insulin Treatment Behaviour: a Major Cause of Ketoacidosis in the Young Adult. <i>Diabetic Medicine</i> , 1995, 12, 429-432.	1.2	41
26	Clinical and molecular characteristics of isolated colonic Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1667-1677.	0.9	38
27	Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence. <i>BioDrugs</i> , 2019, 33, 241-253.	2.2	34
28	Improving outpatient services: the Southampton IBD virtual clinic. <i>Postgraduate Medical Journal</i> , 2012, 88, 487-491.	0.9	32
29	Life in lockdown: experiences of patients with IBD during COVID-19. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000541.	1.1	32
30	Review article: treating a target for inflammatory bowel disease-associated anaemia. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 610-617.	1.9	28
31	Early real-world effectiveness of ustekinumab for Crohn's disease. <i>Frontline Gastroenterology</i> , 2020, 11, 111-116.	0.9	28
32	JAK1 inhibition and inflammatory bowel disease. <i>Rheumatology</i> , 2021, 60, ii45-ii51.	0.9	27
33	Association between genetic variants in myosin IXB and Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1014-1021.	0.9	25
34	Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 500-507.	0.9	24
35	Clinical Implications of Inflammatory Bowel Disease Genetics on Phenotype. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 56-61.	0.9	23
36	Transitioning from Intravenous to Subcutaneous Vedolizumab in Patients with Inflammatory Bowel Disease [TRAVELESS]. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 911-921.	0.6	21

#	ARTICLE	IF	CITATIONS
37	Nutrition and inflammatory bowel disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2011, 14, 491-496.	1.3	18
38	Improving outpatient services: the Southampton IBD virtual clinic. <i>Frontline Gastroenterology</i> , 2012, 3, 76-80.	0.9	18
39	MicroRNAs in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1160-1165.	0.9	18
40	Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. <i>MABs</i> , 2021, 13, 1868078.	2.6	17
41	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapyâ€“Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018, 16, 522-528.	1.0	17
42	Anti-TNF biosimilars in Crohnâ€™s Disease: a patient-centric interdisciplinary approach. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 731-738.	1.4	16
43	Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005â€“2013. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 176-192.	1.9	15
44	Association of <i>caspase-9</i> and <i>RUNX3</i> with inflammatory bowel disease. <i>Tissue Antigens</i> , 2011, 77, 23-29.	1.0	14
45	MicroRNA-31 Targets Thymic Stromal Lymphopoietin in Mucosal Infiltrated CD4+ T Cells: A Role in Achieving Mucosal Healing in Ulcerative Colitis?. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2377-2385.	0.9	12
46	High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000532.	1.1	10
47	Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1653-1661.	0.6	9
48	The impact of an inflammatory bowel disease nurse-led biologics service. <i>Frontline Gastroenterology</i> , 2016, 7, 283-288.	0.9	8
49	MicroRNA23a Overexpression in Crohnâ€™s Disease Targets Tumour Necrosis Factor Alpha Inhibitor Protein 3, Increasing Sensitivity to TNF and Modifying the Epithelial Barrier. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 381-392.	0.6	8
50	A Systematic Review on Infliximab Biosimilar SB2: From Pre-Clinical Data to Real-World Evidence. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 203-223.	1.4	8
51	Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice. <i>Digestive and Liver Disease</i> , 2020, 52, 1259-1265.	0.4	7
52	Hypopituitarism following Coronary Artery Bypass Surgery. <i>Scottish Medical Journal</i> , 1997, 42, 116-117.	0.7	6
53	Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000530.	1.1	6
54	A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK. <i>Medicine (United States)</i> , 2019, 98, e14681.	0.4	5

#	ARTICLE	IF	CITATIONS
55	Tuberculosis and TNF-inhibitors: history of exposure should outweigh investigations. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013202127-bcr2013202127.	0.2	5
56	Inflammatory bowel disease registries for collection of patient iron parameters in Europe. <i>World Journal of Gastroenterology</i> , 2018, 24, 1063-1071.	1.4	4
57	Impact of direct-access IBD physician delivered endoscopy on clinical outcomes: a pre-implementation and post-implementation study. <i>Frontline Gastroenterology</i> , 2022, 13, 477-483.	0.9	2
58	Sa1196 Prospective, Randomized, Double-Blind, Sham-Treatment Controlled Multi-Center Study to Evaluate Efficacy and Safety of Leukocytapheresis (LCAP) Using ACD-A As Anticoagulant in Patients With Steroid-Free, Active Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 144, S-226.	0.6	1
59	Su1228 Thiopurine Withdrawal for Sustained Remission in IBD: A UK Multicentre Study. <i>Gastroenterology</i> , 2013, 144, S-433-S-434.	0.6	1
60	Editorial: CT-EP13, a biosimilar of anti-tumour necrosis factor- α agent (infliximab), in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1370-1371.	1.9	1
61	Roundtable on registries: practical considerations for registries "making them work, London, UK, 26 January 2017. <i>GaBI Journal</i> , 2017, 6, 122-134.	0.4	1
62	The effects of an integrated education programme on the management of diabetic ketoacidosis. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 1995, 12, 235-237.	0.2	0
63	298 The Genetics of Nod-like Receptor Proteins in Crohn's Disease. <i>Gastroenterology</i> , 2008, 134, A-42.	0.6	0
64	W1257 The Arg381Gln SNP in IL 23 R Does Not Influence Response to Immunomodulators in Ulcerative Colitis or Crohn's Disease. <i>Gastroenterology</i> , 2008, 134, A-666.	0.6	0
65	W1258 The Combined Effect of the Aicartase C347g and the Aldehyde Oxidase A3505g SNPs Predict Efficacy of Methotrexate Therapy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2008, 134, A-666.	0.6	0
66	W1847 Prevalence and Determinants of PSC in a Cohort of Patients with Inflammatory Bowel Disease and Normal Liver Function Tests. <i>Gastroenterology</i> , 2008, 134, A-837.	0.6	0
67	S1132 Neoplasia Within 10 Years of Diagnosis of Ulcerative Colitis. <i>Gastroenterology</i> , 2009, 136, A-196.	0.6	0
68	S1142 The Pattern and Outcome of Acute Severe Colitis. <i>Gastroenterology</i> , 2009, 136, A-199.	0.6	0
69	Tu1925 MicroRNA Expression in Treatment Naive Active and Inactive Ulcerative Colitis. <i>Gastroenterology</i> , 2012, 142, S-879.	0.6	0
70	Sa1923 The Role of Histone Deacetylase Inhibition in Ex Vivo and In Vitro Models of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2012, 142, S-360.	0.6	0
71	A man with bloody diarrhoea. <i>BMJ: British Medical Journal</i> , 2012, 344, e978-e978.	2.4	0
72	Mo1728 Cytokine and microRNA Expression in Colonic and Ileal Crohn's Disease Is Modified by Drug Therapy in an Ex Vivo Model. <i>Gastroenterology</i> , 2015, 148, S-695-S-696.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Mo1727 Drug Therapies in Ulcerative Colitis Influence the Expression of MicroRNAs and Cytokines in the Sigmoid Mucosa in an Ex Vivo Model. <i>Gastroenterology</i> , 2015, 148, S-695.	0.6	0
74	Sa1830 microRNA23a Is Overexpressed in the Colonic Epithelium in Crohn's Disease. <i>Gastroenterology</i> , 2016, 150, S375.	0.6	0
75	Transcriptomic Profiling of Intestinal Macrophages Isolated from Patients Reveals a Profound Gene Expression Reprogramming Underlying IBD Pathogenesis. <i>Gastroenterology</i> , 2017, 152, S612.	0.6	0
76	A Novel Alternative to Colectomy for Severe Intractable Constipation in Adults: How to Avoid Surgery in Severe Cases?. <i>Archives of Clinical and Medical Case Reports</i> , 2019, 03, .	0.0	0
77	The monitoring and incidence of hyperglycaemia in inflammatory bowel disease patients treated with intravenous steroids. <i>Clinical Medicine</i> , 2019, 19, s20-s20.	0.8	0